iCo Therapeutics Inc.   Report issue

For profit Phase 2
Founded: Vancouver BC Canada (2005)
Status: Acquired by Satellos Bioscience (2021)

Organization Overview

First Clinical Trial
2008
NCT00886808
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

ico-007 (2 trials)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 2)

Macular Edema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2